Estrella Immunopharma, Inc.
ESLAW· Nasdaq
Released Nov 14, 2024, after the close
10-Q filed Nov 14, 2024, 45 days after period end · 0001213900-24-098450
No earnings release is on file for this quarter. Its figures came with the 10-Q.
| Metric | Q3 2024 | Q3 2021 |
|---|---|---|
| Net Income | -$3.38M | -$107.55K |
| EPS Diluted | -$0.09 | -$0.99 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Estrella Immunopharma, Inc. · CIK 1844417 · Engraved from SEC EDGAR
ended Sep 30, 2024 · filed Nov 14, 2024 · 45 d after period end